Antituberculosis medications

24,974views

Antituberculosis medications

Dr. Andrews

Dr. Andrews

Cell cycle
Oncogenes and tumor suppressor genes
Non-Hodgkin lymphoma
Hodgkin lymphoma
DiGeorge syndrome
Hydronephrosis
Acute pyelonephritis
Chronic pyelonephritis
Vesicoureteral reflux
Bladder exstrophy
BK virus (Hemorrhagic cystitis)
Non-urothelial bladder cancers
Development of the umbilical cord
Development of the fetal membranes
Dizziness and vertigo: Clinical
Reactive arthritis
Klinefelter syndrome
Testicular tumors: Pathology review
DNA alkylating medications
Androgens and antiandrogens
PDE5 inhibitors
Adrenergic antagonists: Alpha blockers
Estrogens and antiestrogens
Progestins and antiprogestins
Aromatase inhibitors
Uterine stimulants and relaxants
Anatomy of the pelvic cavity
Pelvic inflammatory disease
Vulvar cancer: Clinical
Vaginal and vulvar disorders: Pathology review
Chlamydia trachomatis
Papulosquamous skin disorders: Clinical
Transitional cell carcinoma
Human papillomavirus
Paget disease of the breast
Vascular tumors
Development of the digestive system and body cavities
Nephroblastoma (Wilms tumor)
Development of the renal system
Antimetabolites for cancer treatment
Hypothyroidism: Pathology review
Hashimoto thyroiditis
Hyperthyroidism: Pathology review
Thyroid cancer
Thyroid nodules and thyroid cancer: Pathology review
Riedel thyroiditis
Waterhouse-Friderichsen syndrome
Hyperaldosteronism
Adrenal masses and tumors: Clinical
Sheehan syndrome
Cervical cancer
Ovarian cyst
Pheochromocytoma
Multiple endocrine neoplasia: Pathology review
Carcinoid syndrome
Vaginal cancer: Clinical
Acromegaly
Multiple endocrine neoplasia
Parathyroid hormone
Cystic fibrosis
Preeclampsia & eclampsia
Necrotizing enterocolitis
Neonatal respiratory distress syndrome
Galactosemia
Phenylketonuria (NORD)
WAGR syndrome
Focal segmental glomerulosclerosis (NORD)
Nephrotic syndromes: Pathology review
Membranoproliferative glomerulonephritis
Nephritic syndromes: Pathology review
IgA nephropathy (NORD)
Diabetic nephropathy
Membranous nephropathy
Minimal change disease
Ribonucleotide reductase inhibitors
Alport syndrome
Rapidly progressive glomerulonephritis
Goodpasture syndrome
Neurogenic bladder
Polycystic ovary syndrome
Endometrial hyperplasia
Renal system anatomy and physiology
Medullary cystic kidney disease
Krukenberg tumor
Polycystic kidney disease
Multicystic dysplastic kidney
Medullary sponge kidney
Horseshoe kidney
The role of the kidney in acid-base balance
Pancreatic cancer
Pancreatic neuroendocrine neoplasms
Acute pancreatitis
Chronic pancreatitis
Microtubule inhibitors
Bordetella pertussis (Whooping cough)
Topoisomerase inhibitors
Breast cancer
Prostate disorders and cancer: Pathology review
Antidiuretic hormone
Estrogen and progesterone
Li-Fraumeni syndrome
Renal agenesis
Gene regulation
Familial adenomatous polyposis
Mendelian genetics and punnett squares
Uterine fibroid
Respiratory acidosis
Legionella pneumophila (Legionnaires disease and Pontiac fever)
Antituberculosis medications
Cell wall synthesis inhibitors: Cephalosporins
Cell wall synthesis inhibitors: Penicillins
Peutz-Jeghers syndrome
Anatomy of the perineum

Transcript

Watch video only

Antituberculosis medications are agents used to treat tuberculosis, a disease caused by the bacteria Mycobacterium tuberculosis.

Mycobacteria are an interesting bunch, they’re slender, rod-shaped, and need oxygen to survive, in other words, they’re “strict aerobes.”

They’ve got an unusually waxy cell wall, which is mainly a result of the production of mycolic acid.

This waxy cell wall makes them incredibly hardy, and allows them to resist weak disinfectants and survive on dry surfaces for months at a time.

Antituberculosis medications act mainly by preventing the production of mycolic acid and the synthesis of this cell wall.

Although about two billion people worldwide are infected with tuberculosis, or simply ‘TB, the vast majority, about 90-95%, don’t develop symptoms. And this is because usually the immune system can contain it.

So Mycobacterium tuberculosis is usually transmitted via inhalation, which is how they gain entry into the lungs.

TB can avoid the mucus traps and make its way to the deep airways and alveoli where we have macrophages which eat up foreign cells, digest, and destroy them.

With TB, they recognize foreign proteins on their cell surface, and phagocytize them, or essentially package them into a space called a phagosome.

With most cases, the macrophage then fuses the phagosome with a lysosome, which has hydrolytic enzymes that can pretty much break down any biochemical molecule.

TB’s tricky though, and once inside the macrophage, they produce a protein that inhibits this fusion, which allows the mycobacterium to survive.

It doesn’t just survive, though, it proliferates, and creates a localized infection.

Three weeks after initial infection, cell-mediated immunity kicks in, and immune cells surround the site of TB infection, creating a granuloma.

The tissue inside the middle dies as a result, a process referred to as caseous necrosis. This area is known as a “Ghon focus”.

In some cases, the mycobacteria is killed off by the immune system, and that’s the end of that.

In other cases, even though they were walled off, they remain viable, and are therefore still alive, but they’re just dormant. This stage of the disease is called latent TB.

When a person’s immune system becomes compromised, like with AIDS or with aging, the Ghon focus can be reactivated.

T cells quickly release cytokines to try and control the new outbreak, which forms more areas of caseous necrosis.

This time though, it tends to cavitate, or form cavities, which can allow the bacteria to disseminate.

The bacteria can cause bronchopneumonia; but it can also spread via the vascular system and infect almost every other tissue in the body, called systemic miliary TB.

Fortunately, there are many medications that can treat tuberculosis and they are often used together, in case the bacteria is resistant to one or more of the drugs.

Let’s start with isoniazid. It can be used on its own to treat latent infections and as prophylaxis for people traveling to regions where tuberculosis is common.

Isoniazid can be administered orally or parenterally.

In order to work, it’s first converted by a mycobacterial enzyme called peroxidase, into its active metabolite, iproniazid.

A mutation in the gene that codes for this enzyme helps the bacteria develop resistance, because the mutated enzyme won’t activate the medication.

Iproniazid inactivates enzymes associated with mycolic acid synthesis, and mycolic acid is needed to build bacterial cell walls.

It also inhibits mycobacterial peroxidase, preventing the bacteria from metabolizing hydrogen peroxide, which accumulates inside the cell causing serious damage.

Side effects include rash, fever, and systemic lupus erythematosus, called drug-induced SLE.

It can also cause vitamin B6 deficiency, which leads to anemia and neurological symptoms like dizziness, ataxia, or encephalopathy, but the most common is peripheral neuropathy.

Fortunately, these side effects can be prevented with the administration of pyridoxine, or vitamin B6.

Pyridoxine is also useful as an antidote in case of overdose with isoniazid, which can cause seizures, anion gap metabolic acidosis, and coma.

Last, but not least, patients who receive isoniazid should be assessed monthly for symptoms of hepatitis and jaundice in order to detect this serious potential side effect.

If liver damage is present, the medication should be discontinued right away.

Rifampin is the next medication. It can be administered orally or parenterally and acts by inhibiting mycobacterial RNA polymerase, and therefore, the synthesis of RNA.

A mutation in the gene that codes for this enzyme helps the bacteria develop resistance.

Since rifampin gets widely distributed throughout the body, it can get into urine, saliva, tears, feces and sweat, which turns them orange!

But, the most important side effect is hepatitis, which is more severe at high doses.

Luckily, it’s pretty uncommon, but elderly or alcoholic patients, or those who already have liver disease, are at higher risk.

Rifampin also causes other side effects such as rash, fever, and gastrointestinal symptoms like abdominal pain, diarrhea, nausea, and vomiting.

Now, an important fact is that rifampin is a strong CYP450 enzyme inducer, which means it increases the metabolism of many medications, like ritonavir and other HIV antivirals.

This can be problematic since these people with HIV are at a higher risk of developing active tuberculosis.

Key Takeaways

Anti-tuberculosis (TB) medications are drugs used to treat tuberculosis. Common TB medications include Isoniazid (INH), Rifampin (RIF) Pyrazinamide (PZA), and Ethambutol (EMB). Other TB drugs include Streptomycin, Capreomycin, Amikacin, and Levofloxacin. TB drugs are typically administered in combination, which helps minimize resistance to one of the drugs.

Side effects of TB drugs include vitamin B6 deficiency for isoniazid. This is prevented by taking isoniazid with vitamin B6 supplements (pyridoxine). Other side effects include hepatotoxicity for isoniazid, ethambutol, and pyrazinamide; and thrombocytopenia and neutropenia for Rifampin.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Treatment of Latent Tuberculosis Infection" Annals of Internal Medicine (2017)
  5. "Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis" Cold Spring Harbor Perspectives in Medicine (2015)
  6. "Molecular mechanism of the synergistic activity of ethambutol and isoniazid against Mycobacterium tuberculosis" Journal of Biological Chemistry (2018)
  7. "WHO consolidated guidelines on tuberculosis. Module 4" World Health Organization (2020)